What is BioMarin Pharmaceutical Inc.'s Shariah compliance score?

BioMarin Pharmaceutical Inc. (BMRN) has a Shariah compliance score of 72/100 (Grade: B+, Good) based on AAOIFI screening standards. Scores above 70 typically indicate strong compliance. The score factors in business activity screening and financial ratio analysis including debt levels, interest-bearing deposits, and prohibited income percentages. View the full breakdown at HalalScreener.app.

Does BioMarin Pharmaceutical Inc. pass AAOIFI screening?

BioMarin Pharmaceutical Inc. (BMRN) passes AAOIFI Shariah screening. AAOIFI requires: (1) no primary involvement in prohibited activities like alcohol, gambling, or conventional banking, (2) debt-to-market-cap below 30% (BMRN: 5.2%), (3) interest-bearing deposits below 30% (BMRN: 13.7%), and (4) prohibited income below 5% (BMRN: 2.6%). HalalScreener provides free AAOIFI screening for 10,000+ stocks at halalscreener.app.

How much purification is needed for BioMarin Pharmaceutical Inc. stock?

BioMarin Pharmaceutical Inc. (BMRN) has a non-permissible income ratio of 2.55%. Muslim investors should purify this percentage of any dividends received and capital gains realized from BMRN shares by donating it to charity. HalalScreener's purification calculator at halalscreener.app/en/purification automates this calculation using the latest financial data.

Where can I screen BioMarin Pharmaceutical Inc. for Shariah compliance for free?

HalalScreener (halalscreener.app) offers free Shariah compliance screening for BioMarin Pharmaceutical Inc. (BMRN) and 10,000+ other US-listed stocks, ETFs, and 100+ cryptocurrencies. The screening uses AAOIFI Standard No. 21 and shows all financial ratios transparently. No credit card or signup required for basic screening. HalalScreener also includes an AI Islamic Scholar for follow-up questions about BMRN's compliance across different madhabs (Hanafi, Shafi'i, Maliki, Hanbali, Ja'fari).

BMRN: Is BioMarin Pharmaceutical Inc. Halal?

BioMarin Pharmaceutical Inc.

NASDAQHealthcareUS

$57.22

-0.78%

Market Cap: 11.1B

Compliance Status

Halal

Screened on Jul 15, 2026 · AAOIFI Standard 21

B+

Good

72Score

Is BioMarin Pharmaceutical Inc. (BMRN) halal? Halal. Based on AAOIFI screening, BioMarin Pharmaceutical Inc. passes both qualitative (business activity) and quantitative (financial ratio) screens with a compliance score of 72/100 (Grade: B+).

AvoidBorderlineClean

Business activity

What the company sells is permissible.

Passed

Company debt

Well clear of the limit

How much the company borrows, compared to its total value. AAOIFI allows up to 30%.

5.2% of 30.0% limit

What this means for you

You can own BMRN

It passes both the business activity and financial ratio screens under AAOIFI Standard 21.

Purify 2.6% of your income from BMRN

That is about $2.60 of every $100 you earn from it. Donate this share to charity.

Calculate my exact amount

About BioMarin Pharmaceutical Inc.

BioMarin Pharmaceutical Inc. specializes in creating and bringing to market treatments for individuals suffering from severe and often fatal rare disorders and other critical medical conditions. The company currently markets several key pharmaceutical products. Among these are Vimizim, an enzyme replacement therapy targeting mucopolysaccharidosis (MPS) IV type A, a specific lysosomal storage disorder, and Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for individuals with MPS VI. Another notable offering is Kuvan, a unique synthetic oral version of 6R-BH4, prescribed for phenylketonuria (PKU), an inherited metabolic condition. Further expanding its product portfolio, BioMarin provides Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme administered via subcutaneous injection to lower blood Phe levels. Also available are Brineura, a recombinant human tripeptidyl peptidase 1 used in treating ceroid lipofuscinosis type 2, a variant of Batten disease; Voxzogo, a daily injectable c-type natriuretic peptide analog for achondroplasia; and Aldurazyme, a refined protein mirroring the naturally occurring human enzyme alpha-L-iduronidase. Beyond its established products, BioMarin has a robust development pipeline. This includes valoctocogene roxaparvovec, an adeno-associated virus vector undergoing Phase III clinical trials for severe hemophilia A. Additionally, BMN 307, an AAV5-mediated gene therapy, is in Phase 1/2 trials, aiming to normalize blood phenylalanine levels in PKU patients, while BMN 255 is also in Phase 1/2 trials for primary hyperoxaluria. Its clientele spans specialty pharmacies, hospitals, international government health bodies, and a network of distributors and pharmaceutical wholesalers. These services reach patients and healthcare providers across the United States, Europe, Latin America, and other global markets. BioMarin maintains strategic licensing and collaborative alliances with partners such as Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc., and Asubio Pharma Co., Ltd. Established in 1996, the company's corporate headquarters are located in San Rafael, California.

Sector: Healthcare · Industry: Biotechnology

Shariah Compliance Status

AAOIFI Standard 21Updated Jul 15, 2026

Compliance History

Halal, unchanged since May 2026.

No status changes recorded since we began tracking.

Tracked since May 2026. Updates automatically on each re-screen.

Fiscal: Q1 2026Data source: EDGAR

More Healthcare Stocks

JNJ

Johnson & Johnson

UNH

UnitedHealth Group Incorporated

B+

ABBV

AbbVie Inc.

PFE

Pfizer Inc.

LLY

Eli Lilly and Company

A+

MRK

Merck & Co., Inc.

B+

Free · No credit card required

Track BMRN and 10,000+ stocks with AI insights

Create your free account to unlock AI-powered compliance analysis, track your portfolio, calculate purification, and get unlimited AAOIFI screening.

Get Started Free Browse Screener

10,000+ assets AAOIFI standards Free watchlist

Frequently Asked Questions

Is BioMarin Pharmaceutical Inc. (BMRN) halal to invest in?

Based on AAOIFI Standard 21 screening, BioMarin Pharmaceutical Inc. (BMRN) is rated Halal with a compliance grade of B+ (Good). It passes both the business activity screen (no primary involvement in prohibited sectors) and the quantitative financial ratio screen (debt, interest deposits, and prohibited income all below AAOIFI thresholds).

Why did BioMarin Pharmaceutical Inc. get a B+ compliance rating?

BioMarin Pharmaceutical Inc. (BMRN) received a grade of B+ (Good) based on three AAOIFI Standard 21 financial ratios: debt-to-market-cap of 5.2% (limit 30%); interest-bearing deposits of 13.7% (limit 30%); prohibited income of 2.55% (limit 5%). The grade reflects the margin of safety across all three ratios relative to their thresholds.

What could change BioMarin Pharmaceutical Inc.'s Shariah verdict?

BioMarin Pharmaceutical Inc.'s verdict is re-evaluated at each annual re-screen. Three events could change it: (1) the debt-to-market-cap ratio crossing 30%, typically from new debt issuance or a major drop in share price; (2) interest-bearing deposits exceeding 30% of market cap; or (3) prohibited revenue (alcohol, gambling, conventional finance, etc.) exceeding 5% of total revenue. Verdict flips are tracked in the compliance history section above.

How often is BioMarin Pharmaceutical Inc. re-screened for Shariah compliance?

BioMarin Pharmaceutical Inc. (BMRN) is re-screened annually using the most recent full-year financial data from SEC filings. HalalScreener also triggers an on-demand re-screen whenever the stored data is more than 7 days old, ensuring the ratios reflect the latest available financial statements. Last screened: Jul 15, 2026.

Screened according to AAOIFI Standard No. 21 · For informational purposes only. Consult a qualified Islamic finance advisor before investing.

Disclaimer: This screening is for informational purposes only and does not constitute financial, legal, or religious advice. Compliance is evaluated using AAOIFI financial standards (debt, deposits, and prohibited income ratios) and publicly available data. Ethical, political, social, or environmental considerations are outside the scope of this screening. Individual scholars and methodologies may differ. Always consult a qualified Islamic finance advisor before making investment decisions.